Table 2.
Demographic and Clinical Characteristics by Tubal Ligation Status and Type of Endometrial Cancer. Characteristics of women in the study cohort comparing women with and without tubal ligation and with and without endometrial carcinoma. Characteristics ultimately utilized in multivariate models.
| Demographic | No Tubal Ligation (n=61,984) | Tubal Ligation (n=14,499) | ||||
|---|---|---|---|---|---|---|
|
| ||||||
| No Endometrial Cancer (n=61,039) | Type I (n=810) | Type II (n=135) | No Endometrial Cancer (n=14,307) | Type I (n=162) | Type II (n=30) | |
|
| ||||||
| Region : | ||||||
| Northeast | 16755 (27%) | 226 (28%) | 38 (28%) | 3308 (23%) | 41 (25%) | 8 (27%) |
| South | 13207 (22%) | 173 (21%) | 30 (22%) | 3805 (27%) | 39 (24%) | 4 (13%) |
| Midwest | 13492 (22%) | 177 (22%) | 33 (24%) | 3412 (24%) | 34 (21%) | 5 (17%) |
| West | 17585 (29%) | 234 (29%) | 34 (25%) | 3782 (26%) | 48 (30%) | 13 (43%) |
|
| ||||||
| Age stratum at randomization or enrollment: | ||||||
| 50 – 54 | 6652 (11%) | 70 (9%) | 10 (7%) | 3715 (26%) | 33 (20%) | 1 (3%) |
| 55 – 59 | 11065 (18%) | 148 (18%) | 27 (20%) | 4810 (34%) | 52 (32%) | 9 (30%) |
| 60 – 69 | 28370 (46%) | 390 (48%) | 56 (41%) | 4908 (34%) | 68 (42%) | 17 (57%) |
| 70 – 79 | 14952 (24%) | 202 (25%) | 42 (31%) | 874 (6%) | 9 (6%) | 3 (10%) |
|
| ||||||
| Ethnicity : | ||||||
| Asian or Pacific Islander | 1840 (3%) | 8 (1%) | 2 (1%) | 483 (3%) | 4 (2%) | 1 (3%) |
| Black or African-American | 3821 (6%) | 28 (3%) | 10 (7%) | 1358 (9%) | 7 (4%) | 1 (3%) |
| Hispanic/Latino | 1882 (3%) | 7 (1%) | 4 (3%) | 682 (5%) | 5 (3%) | 1 (3%) |
| White (not of Hispanic origin) | 52453 (86%) | 752 (93%) | 118 (87%) | 11522 (81%) | 141 (87%) | 27 (90%) |
| American Indian or Alaskan | 862 (1%) | 11 (1%) | 1 (1%) | 234 (2%) | 5 (3%) | 0 |
| Native /Other Missing | 181 (<1%) | 4 (<1%) | 0 | 28 (<1%) | 0 | 0 |
|
| ||||||
| Age at menarche: | ||||||
| < 12 | 12444 (20%) | 180 (22%) | 15 (11%) | 3235 (23%) | 53 (33%) | 1 (3%) |
| 12 – 13 | 34077 (56%) | 496 (61%) | 66 (49%) | 7813 (55%) | 75 (46%) | 19 (63%) |
| 14+ | 14384 (24%) | 131 (16%) | 22 (16%) | 3230 (23%) | 34 (21%) | 5 (17%) |
| Missing | 134 (<1%) | 3 (<1%) | 32 (24%) | 29 (<1%) | 0 | 5 (17%) |
|
| ||||||
| Age at menopause: Mean (SD)(min, max) | 50.4 (SD=4.9) (20, 60) | 51 (SD=4.6) (30, 60) | 51.8(SD=4.6) (36, 60) | 50 (SD=4.4) (20, 60) | 50.1 (SD=5.1) (34, 60) | 52 (SD=4.4) (42, 60) |
|
| ||||||
| Number of term pregnancies: | ||||||
| Never pregnant | 7604 (12%) | 124 (15%) | 16 (12%) | 370 (3%) | 6 (4%) | 0 |
| No term pregnancy | 1910 (3%) | 29 (4%) | 6 (4%) | 243 (2%) | 4 (2%) | 0 |
| 1 | 5790 (9%) | 74 (9%) | 11 (8%) | 949 (7%) | 12 (7%) | 4 (13%) |
| 2 | 15560 (25%) | 218 (27%) | 33 (24%) | 3872 (27%) | 39 (24%) | 4 (13%) |
| 3 | 14037 (23%) | 199 (25%) | 28 (21%) | 3956 (28%) | 56 (35%) | 7 (23%) |
| 4 | 8300 (14%) | 96 (12%) | 24 (18%) | 2558 (18%) | 22 (14%) | 9 (30%) |
| 5+ | 7564 (12%) | 68 (8%) | 16 (12%) | 2291 (16%) | 22 (14%) | 6 (20%) |
| Missing | 274 (<1%) | 2 (<1%) | 1 (1%) | 68 (<1%) | 1 (1%) | 0 |
|
| ||||||
| Oral contraceptive use ever at screening: | ||||||
| No | 37537 (61%) | 522 (64%) | 85 (63%) | 5909 (41%) | 75 (46%) | 16 (53%) |
| Yes | 23502 (39%) | 288 (36%) | 50 (37%) | 8398 (59%) | 87 (54%) | 14 (47%) |
|
| ||||||
| Unopposed estrogen usage status at screening: | ||||||
| Never used | 53604 (88%) | 646 (80%) | 119 (88%) | 12855 (90%) | 133 (82%) | 25 (83%) |
| Past user | 5940 (10%) | 117 (14%) | 12 (9%) | 1037 (7%) | 18 (11%) | 4 (13%) |
| Current user | 1476 (2%) | 46 (6%) | 4 (3%) | 410 (3%) | 11 (7%) | 1 (3%) |
| Missing | 19 (<1%) | 1 (<1%) | 0 | 5 (<1%) | 0 | 0 |
|
| ||||||
| Diabetes ever at screening: | ||||||
| No | 57986 (95%) | 766 (95%) | 123 (91%) | 13660 (95%) | 153 (94%) | 30 (100%) |
| Yes | 3013 (5%) | 44 (5%) | 12 (9%) | 634 (4%) | 9 (6%) | 0 |
| Missing | 40 | 0 | 0 | 13 (<1%) | 0 | 0 |
|
| ||||||
| Diabetes now at screening: | ||||||
| No | 641 (22%) | 10 (23%) | 10 (23%) | 144 (23%) | 2 (22%) | 0 |
| Yes | 2327 (78%) | 34 (77%) | 34 (77%) | 483 (77%) | 7 (78%) | 0 |
|
| ||||||
| Bilateral oophorectomy at screening: | ||||||
| No | 60495 (99%) | 803 (99%) | 134 (99%) | 14205 (99%) | 161 (99%) | 30 (100%) |
| Yes | 392 (1%) | 6 (1%) | 0 | 60 | 1 (1%) | 0 |
| Missing | 152 (<1%) | 1 (<1%) | 1 (1%) | 42 (<1%) | 0 | 0 |
|
| ||||||
| BMI: Mean (SD)(min, max) | 27.3 (SD=5.8) (11.9, 69.6) | 29.2 (SD=7.1) (12.9, 66.2) | 28.7 (SD=6.2) (18, 50) | 27.7 (SD=6) (12, 69.9) | 29.5 (SD=7.6) (18.4, 59.1) | 27.8 (SD=5.5) (21, 41.3) |
| BMI at screening, categorized: | ||||||
| Underweight (<18.5) | 722 (1%) | 6 (1%) | 1 (1%) | 130 (1%) | 1 (1%) | 0 |
| Normal (18.5 – 24.9) | 23784 (39%) | 266 (33%) | 46 (34%) | 5280 (37%) | 51 (31%) | 12 (40%) |
| Overweight (25.0 – 29.9) | 20801 (34%) | 224 (28%) | 38 (28%) | 4833 (34%) | 48 (30%) | 10 (33%) |
| Obesity I (30.0 – 34.9) | 9883 (16%) | 165 (20%) | 28 (21%) | 2467 (17%) | 30 (19%) | 4 (13%) |
| Obesity II (35.0 – 39.9) | 3760 (6%) | 83 (10%) | 17 (13%) | 1001 (7%) | 17 (10%) | 3 (10%) |
| Obesity III (≥40) | 1984 (3%) | 65 (8%) | 5 (4%) | 571 (4%) | 15 (9%) | 1 (3%) |
| Missing | 105 (<1%) | 1 (<1%) | 0 | 25 (<1%) | 0 | 0 |